STRIKE A NERVE
agency: Unit 7
brand: Lyrica
client: Pfizer
photo from left: Steve Capp, chief creative officer, copywriter • Mickey Paxton, SVP, group creative director, art director • Jeff Harris, executive creative director • Paul Mellet, executive producer • Ross Quinn, chief collaboration officer
Pain is no laughing matter. But the team at Unit 7 managed to incorporate humor into its unbranded commercial for Pfizer's Lyrica in a way that brought the product closer to patients.
The campaign features the Nerve Man, a nefarious brute who torments diabetes sufferers with shooting, stabbing, burning pain. "People are dealing with this pain day in and day out," says Steve Capp, chief creative officer for Unit 7. "There is a fine line that you walk for anything dealing with pharmaceuticals. People's quality of life is affected, so will the Nerve Man be seen as humorous or are they going to be offended by it? We did our homework; we asked the questions. When we did the testing, people reacted in the right way."
Capp and teammate Mickey Paxton found initial inspiration for the Nerve Man concept in Trilogy of Terror, a series of three campy made-for-TV horror films that aired on ABC in the 1970s. In one of the films, a doll terrorizes actress Karen Black by repeatedly attacking her. While Unit 7 certainly didn't want to make a terrifying commercial, the team did want to communicate the idea of an enemy who can strike at any moment. Enter the Nerve Man.
The audition process was grueling, with nearly 100 actors lining up to get the part. But when the team met Schuler Hensley, they knew they had their man. "He just hit it right on the head and delivered exactly what we were looking for," says Capp. "It's a bit John Belushi, a bit Jack Black, a bit Lou Costello." (Currently, Hensley is appearing on Broadway in a star-making turn as the Monster in the musical Young Frankenstein.) The fact that Hensley is physically imposing also augments the message that diabetic nerve pain truly compromises one's quality of life and can't simply be brushed off as a minor nuisance.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.